Stockscreener 앱 받기
5.05
3.48%
0.17
Diamedica Therapeutics Inc 주식(DMAC)의 최신 뉴스
What drives DiaMedica Therapeutics Inc. stock priceRapidly growing investment returns - PrintWeekIndia
Ischemic Stroke Pipeline Experiences Rapid Expansion as Over 50+ Leading Companies Advance Novel Therapies - The Globe and Mail
DiaMedica gains on positive mid-stage trial data for lead drug in preeclampsia - MSN
DiaMedica Therapeutics Inc. Stock Analysis and ForecastFree Market Volatility Navigation Tips - PrintWeekIndia
Is DiaMedica Therapeutics Inc. stock overhyped or has real potentialBreakthrough financial growth - jammulinksnews.com
DiaMedica raises $30.1M in private placement for preeclampsia, stroke treatment - The Business Journals
The Beat: Entrust names new CEO, DiaMedica raises millions - The Business Journals
DiaMedica Therapeutics Announces Closing of $30.1 Million Private Placement - BioSpace
DiaMedica Therapeutics Secures $30.1 Million in Private Placement - TipRanks
DiaMedica Therapeutics closes $30.1 million private placement - Investing.com India
DiaMedica Therapeutics closes $30.1 million private placement By Investing.com - Investing.com UK
Is DiaMedica Therapeutics Inc. a good long term investmentDynamic profit expansion - jammulinksnews.com
What analysts say about DiaMedica Therapeutics Inc. stockFree Stock Market Knowledge Sharing - jammulinksnews.com
Diamedica Therapeutics shares rise 11.01% intraday after $30.1M private placement and positive trial results for DM199 in preeclampsia. - AInvest
DiaMedica Therapeutics to sell 8.606M shares at $3.50 in private placement - TipRanks
DiaMedica Announces $30.1M Private Placement for DM199 - TipRanks
DiaMedica secures $30.1 million in private placement for clinical trials - Investing.com Australia
DiaMedica secures $30.1 million in private placement for clinical trials By Investing.com - Investing.com South Africa
DiaMedica Therapeutics Raises $30 Million in Private Placement to Accelerate Industry Leading Preeclampsia and Fetal Growth Restriction Pipeline - Business Wire
DiaMedica Therapeutics (NASDAQ:DMAC) Given New $11.00 Price Target at Craig Hallum - MarketBeat
DiaMedica Therapeutics (NASDAQ:DMAC) Price Target Raised to $12.00 - Defense World
DiaMedica shares drop 35% following InvestingPro’s overvalued warning By Investing.com - Investing.com India
What makes DiaMedica Therapeutics Inc. stock price move sharplyReliable High Profit Alerts - beatles.ru
DiaMedica stock price target raised to $12 from $10 at H.C. Wainwright - Investing.com Nigeria
DiaMedica Therapeutics to be included in the Russell 2000 and 3000 indexes - MSN
DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer - BioSpace
DiaMedica Therapeutics reports interim results from DM199 study - TipRanks
DiaMedica Announces Positive Interim Results for DM199 Study - TipRanks
DiaMedica reports positive interim results for preeclampsia treatment - Investing.com
Why DiaMedica Therapeutics Inc. stock attracts strong analyst attentionVerified Return Tips - Newser
How DiaMedica Therapeutics Inc. stock performs during market volatilityValue Pick Scanner - Newser
3 Promising Penny Stocks With Market Caps Under $200M - simplywall.st
0.97%
0.22%
자본화:
|
볼륨(24시간):